Pay in 4 interest-free payments of $5.70 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
It is the first FDA- approved drug since 2017 for chronic weight management in overweight adults with obesity
A study of 559 Blue Sky MD patients showed an average weight loss of 13% in just 12 weeksthats nearly 30 pounds in just 3 months and more than double what patients see with Wegovy alone.* Individual results may vary
Medicare Utilization of GLP-1s Rises with Broader Indications Beyond Obesity Since Medicare does not cover anti obesity drugs when prescribed solely for weight management, utilization of weight loss indicated GLP-1s historically lagged behind their use in commercial markets
A notable secondary finding was the reduction in cigarette consumption among participants who smoked, suggesting semaglutides potential for broader substance use treatment
Not for use in diagnostic procedures, human use, or veterinary use
US$ 26.68
.png)
US$ 29.07
US$ 26.97
US$ 21.35
US$ 22.65
US$ 24.89
